LA JOLLA, CA — February 5, 2026 — Leads & Copy — GRI Bio, Inc. (NASDAQ: GRI) will participate in the Corporate Connect Webinar Series hosted by Webull Financial, held virtually from February 10-11, 2026, the company announced today.
The presentation is scheduled for Wednesday, February 11, 2026, at 1:00 PM EST. Marc Hertz, PhD, President, Chief Executive Officer, and Director of GRI Bio, will be the presenter. Interested parties can register via the provided link.
GRI Bio is a clinical-stage biopharmaceutical company focused on changing the way inflammatory, fibrotic, and autoimmune diseases are treated. Their therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis.
Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an RARβγ agonist shown to inhibit the activity of key immune cells, like iNKT cell activity, and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need.
The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Webull Financial is an online brokerage platform empowering self-directed investors with tools and technology. It offers low-cost trading, advanced charting tools, and real-time market data. Webull Financial LLC is a broker-dealer registered with the SEC and a futures commission merchant registered with the CFTC. It is a member of FINRA, the NFA, and the SIPC.
All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.
Source: GRI Bio, Inc.
